Laboratories VIVACY Appoints Katie Hughes-Dawkins as Sales Director for UK and Ireland
Premium injectable manufacturer Laboratoires VIVACY has appointed Katie Hughes-Dawkins as Sales Director for the UK and Ireland, strengthening the company’s commercial leadership as it continues to expand its footprint in medical aesthetics. Hughes-Dawkins brings more than 25 years of sector experience spanning clinical practice, sales leadership and brand development, with a track record in revenue growth, team building and relationship management across clinics, practitioners and key opinion leaders.
The appointment comes at a significant stage for Laboratoires VIVACY, the French aesthetics company founded in 2007 and known internationally for its hyaluronic acid-based injectable portfolio. The business operates in more than 70 countries and manufactures its products in France, with production and logistics based in Archamps. Its portfolio spans facial aesthetics, women’s intimate health, dermo-cosmetics, ophthalmic surgery and viscosupplementation, positioning the company as a broad medical aesthetics player rather than a single-brand filler house.
Within aesthetics, VIVACY is best known for STYLAGE, its premium dermal filler line, supported by patented technologies including IPN-Like for hyaluronic acid cross-linking and Bi-SOFT injection technology, both designed to support injectability, precision and product performance in clinical practice. The company also places a strong emphasis on practitioner support through VIVACY Academy, which offers training, webinars, safety education and scientific resources for healthcare professionals.
Commenting on her appointment, Hughes-Dawkins said: “VIVACY represents innovation, scientific integrity and long-term partnership; and I am delighted to be joining at such an exciting time for the brand and lead the next phase of growth in the UK and Ireland.”
“2026 marks the beginning of a new era for VIVACY. With the introduction of Rejuran, the number one South Korean polynucleotide treatment, and the launch of Novuma, a next-generation calcium hydroxyapatite, alongside our premium STYLAGE dermal fillers and DESIRIAL intimate gels, we now offer one of the most comprehensive regenerative medicine portfolios for aesthetic applications” added Brianna Broadbridge, VIVACY UK General Manager.
We are delighted to welcome Katie Hughes-Dawkins as our National Sales Director for the UK and Ireland at such a pivotal moment for the company. Her deep experience and knowledge of the aesthetics market, combined with her impeccable reputation and strong focus on customer needs, will be a tremendous asset as we continue to strengthen VIVACY’s presence in the region”.
VIVACY has also been building momentum internationally through product and partnership activity. In March 2025, the company announced a strategic collaboration with Burgeon Biotechnology to combine its STYLAGE hyaluronic acid expertise with NOVUMA, a calcium hydroxyapatite biostimulator, marking a move further into regenerative aesthetics. Later in 2025, VIVACY also announced the global launch of its Bi-FLEX syringe, a next-generation injection technology developed to enhance control and handling for practitioners.
